Effects of novel HDAC inhibitors on urothelial carcinoma cells

BACKGROUND: Histone deacetylase inhibitors (HDACi) are promising anti-cancer drugs that could also be employed for urothelial carcinoma (UC) therapy. It is unclear, however, whether inhibition of all 11 zinc-dependent HDACs or of individual enzymes is more efficacious and specific. Here, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaletsch, Aline, Pinkerneil, Maria, Hoffmann, Michèle J., Jaguva Vasudevan, Ananda A., Wang, Chenyin, Hansen, Finn K., Wiek, Constanze, Hanenberg, Helmut, Gertzen, Christoph, Gohlke, Holger, Kassack, Matthias U., Kurz, Thomas, Schulz, Wolfgang A., Niegisch, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069857/
https://www.ncbi.nlm.nih.gov/pubmed/30064501
http://dx.doi.org/10.1186/s13148-018-0531-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069857/
https://www.ncbi.nlm.nih.gov/pubmed/30064501
http://dx.doi.org/10.1186/s13148-018-0531-y

Ejemplares similares